Lincoln Pharmaceuticals Ltd banner

Lincoln Pharmaceuticals Ltd
NSE:LINCOLN

Watchlist Manager
Lincoln Pharmaceuticals Ltd Logo
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
Watchlist
Price: 495 INR 0.22%
Market Cap: ₹9.9B

Relative Value

The Relative Value of one LINCOLN stock under the Base Case scenario is hidden INR. Compared to the current market price of 495 INR, Lincoln Pharmaceuticals Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LINCOLN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

LINCOLN Competitors Multiples
Lincoln Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
10B INR 1.6 11.5 7.8 8.9
US
Eli Lilly and Co
NYSE:LLY
992.9B USD 15.2 48.1 32.4 34.5
US
Johnson & Johnson
NYSE:JNJ
575.5B USD 6.1 21.5 14.9 18.3
CH
Roche Holding AG
SIX:ROG
282.2B CHF 4.6 30 12.7 14.8
CH
Novartis AG
SIX:NOVN
231.1B CHF 5.3 21.2 13.1 16.8
UK
AstraZeneca PLC
LSE:AZN
215.7B GBP 5.1 31.8 15.2 22.2
US
Merck & Co Inc
NYSE:MRK
291.1B USD 4.5 16 10 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.5 9.9 11.6
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
153.9B USD 2.5 19.8 7.4 9.9
US
Bristol-Myers Squibb Co
NYSE:BMY
123.2B USD 2.6 17.5 6.8 8.8
P/E Multiple
Earnings Growth PEG
IN
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
Average P/E: 23.1
11.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.1
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.5
7%
3.1
CH
Roche Holding AG
SIX:ROG
30
29%
1
CH
Novartis AG
SIX:NOVN
21.2
15%
1.4
UK
AstraZeneca PLC
LSE:AZN
31.8
38%
0.8
US
Merck & Co Inc
NYSE:MRK
16
14%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
13.5
7%
1.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
19.8
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.5
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
Average EV/EBITDA: 42.1
7.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.4
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
14.9
2%
7.5
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
CH
Novartis AG
SIX:NOVN
13.1
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
15.2
10%
1.5
US
Merck & Co Inc
NYSE:MRK
10
7%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
7%
1.4
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.8
-13%
N/A